Alan Parr, PharmD
Dr. Parr has worked in the field of Pharmaceutical Sciences for 33 years. Most of this time has been spent in the big pharma sector (Glaxo, GlaxoWellcome, and GlaxoSmithKline). Dr. Parr’s roles in big pharma including included formulation scientist, formulation manager, and Director of Biopharmaceutics, and responsibilities ranged from the development of formulations from the early development phase all the way through to the scale-up of commercial size batches for the marketplace. Specific activities during this time included physical property characterization, formulation screening, formulation development, manufacture of clinical supplies, transfer of product to production, and overall project management. He was intimately involved with the creation, review, and submission of regulatory documents to the US Food and Drug Administration, including Investigational New Drug (IND) applications, New Drug Applications (NDA) as well as foreign filings (Marketing Authorization Applications (MAA)).
Since June of 2015, Dr. Parr has served as a consultant to numerous small pharmaceutical companies and has served as a principal investor for 2 NIH grants where his primary responsibility was to file an IND for an NCE that was being developed. Dr. Parr earned his Pharm.D. degree from the University of Nebraska College of Pharmacy in 1981 and his Ph.D. from the University of Kentucky College of Pharmacy in 1986.